Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Body unavailable. Use the original source.
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.